Home  >  Research  >  Labs  >  Cancer Program  >  LIVER DISEASE AND CARCINOGENESIS

RESEARCH OVERVIEW

Our research group focuses on the liver progenitor/stem cell (LPSC) which we identify in patients with alcoholic liver disease (ALD), hepatitis C (HCV), genetic hemochromatosis (GH) and non-alcoholic fatty liver disease (NAFLD). An objective of our research is to utilise their presence as a diagnostic to detect early stages of pathology and their abundance as an indicator of disease severity. Since ALD, GH, HCV and NAFLD increase the likelihood of developing hepatocellular carcinoma (HCC), the LPSCs may also be useful as a prognostic for patients who will develop liver cancer.

We are well-placed to undertake these studies as we have a monoclonal antibody that detects the LPSCs in liver biopsies. Our recent studies suggest that the protein this antibody binds to is present in the blood of patients who harbour LPSCs in their liver. This raises the possibility of developing a blood test that informs clinicians of the state of the patient’s liver.

The LPSC is present in diseased liver because it has an important role in repairing the damaged organ. It is a functional stem cell that can produce cholangiocytes that make up the bile ducts; or it can produce hepatocytes that are responsible for the major functions of the liver. To better study this important liver cell, we have established LPSC lines from both the mouse and human to understand what makes them grow and how they decide between generating cholangiocytes and hepatocytes.

This work has produced a valuable resource in the form of LPSC lines that are non-cancerous and others that are tumorigenic. This provides a platform for screening and testing for anti-liver cancer drugs that are selectively effective against liver cancer cells.

 

Emeritus Professor George Yeoh

Emeritus Professor George Yeoh

Liver Disease and Carcinogenesis

Read more

LATEST NEWS

Funding boost to supercharge medical research and innovation

Two Perkins researchers received funding from the Future Health Research and Innovation Fund through the Enabling Scheme and the Research and Innovation Capacity and Capability Building Program last week.  Professor Kevin Pfleger, Director Biomedical and Health Innovation at UWA and the WA Life Sciences Innovation Hub, Chair of Perth Biodesign,…

Read More

Recognition for respected vascular specialist

Director of the Heart and Vascular Research Institute and Joint Program Head of the Cardiovascular Science and Diabetes Program at the Harry Perkins Medical Research Institute, Professor Shirley Jansen has been appointed the Michael Lawrence-Brown Professorial Chair in Vascular Surgery at the School of Population Health at Curtin University.   Professor Jansen (pictured…

Read More

Researchers develop new AI tool to predict heart attack risk

Researchers from the Harry Perkins Institute of Medical Research, working with medtech industry partners Artrya Limited, have developed a new, fully-automated AI algorithm that is more effective than current methods at predicting the risk of heart attack. First author Dr Gavin Huangfu, from the Perkins, The University of Western Australia…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS